Veeva Systems Inc. (NYSE:VEEV) Shares Purchased by B. Metzler seel. Sohn & Co. AG

B. Metzler seel. Sohn & Co. AG raised its position in Veeva Systems Inc. (NYSE:VEEV) by 17.0% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 7,006 shares of the technology company’s stock after acquiring an additional 1,019 shares during the quarter. B. Metzler seel. Sohn & Co. AG’s holdings in Veeva Systems were worth $1,473,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the company. MassMutual Private Wealth & Trust FSB boosted its holdings in shares of Veeva Systems by 72.5% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 119 shares of the technology company’s stock valued at $25,000 after acquiring an additional 50 shares in the last quarter. Centricity Wealth Management LLC acquired a new stake in Veeva Systems in the fourth quarter valued at about $25,000. Smithfield Trust Co boosted its holdings in Veeva Systems by 145.5% in the 4th quarter. Smithfield Trust Co now owns 135 shares of the technology company’s stock valued at $27,000 after purchasing an additional 80 shares in the last quarter. Retirement Wealth Solutions LLC acquired a new position in Veeva Systems during the 4th quarter worth approximately $31,000. Finally, Avion Wealth raised its stake in shares of Veeva Systems by 635.0% during the 4th quarter. Avion Wealth now owns 147 shares of the technology company’s stock worth $30,000 after buying an additional 127 shares in the last quarter. Hedge funds and other institutional investors own 88.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on VEEV shares. Morgan Stanley lifted their price target on Veeva Systems from $195.00 to $201.00 and gave the company an “underweight” rating in a research note on Thursday, March 6th. Truist Financial boosted their target price on shares of Veeva Systems from $210.00 to $217.00 and gave the stock a “hold” rating in a research report on Thursday, March 6th. Canaccord Genuity Group increased their price target on shares of Veeva Systems from $210.00 to $270.00 and gave the company a “hold” rating in a report on Friday, December 6th. Stifel Nicolaus boosted their price objective on shares of Veeva Systems from $240.00 to $272.00 and gave the stock a “buy” rating in a report on Friday, December 6th. Finally, Robert W. Baird increased their target price on shares of Veeva Systems from $283.00 to $285.00 and gave the company an “outperform” rating in a report on Thursday, March 6th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, Veeva Systems has an average rating of “Moderate Buy” and an average price target of $256.52.

Veeva Systems Trading Down 0.6 %

Shares of NYSE:VEEV opened at $226.51 on Thursday. Veeva Systems Inc. has a 12-month low of $170.25 and a 12-month high of $258.93. The stock’s 50-day moving average price is $231.96 and its two-hundred day moving average price is $223.04. The firm has a market cap of $36.85 billion, a price-to-earnings ratio of 55.93, a PEG ratio of 1.89 and a beta of 0.88.

Insider Buying and Selling

In other news, SVP Jonathan Faddis sold 787 shares of the company’s stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $226.20, for a total transaction of $178,019.40. Following the completion of the sale, the senior vice president now directly owns 8,668 shares in the company, valued at $1,960,701.60. This represents a 8.32 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 10.50% of the company’s stock.

About Veeva Systems

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.